|
||
| |||||||
|
With the FDA granting "Fast Track" designation to OXiGENE's lead Vascular Targeting Agent compound (CA4P) for the indication of Anaplastic Thyroid Cancer (ATC) and with OXiGENE filing for an "Orphan" drug status for this product, a frenzied media attention has been cast on the Vascular Targeting Agents class. Attacking tumor blood vessels as a complementary strategy to current cancer treatment modalities has been a concept in development since the early 1960s. After at least US$4 billion in research and development spend and over 10,000 patients being tested by anti-vascular compounds the approach is proving to be both clinically and commercially viable. Compounds that act to deprive tumors of a blood supply fall into two categories angiogenesis inhibitors and vascular targeting agents. The latter have the potential advantage that they are able to damage the existing tumor vasculature, rather than just preventing its further formation by angiogenesis. Vascular Targeting Agents (VTAs) are multifunctional agents that target the capillaries and vessels of solid tumors. Once localized to the tumor blood vessels, these agents are supposed to block the flow of oxygen and nutrients to underlying tumor tissue by activating a thrombotic (blood clotting) pathway. There are currently seven VTAs in clinical trials with many more in pre-clinical development. Three small molecule vascular targeting agents have reached phase II clinical; combretastatin A4 phosphate (CA4P, OXiGENE), ZD6126 (Angiogene/AstraZeneca) and AVE-8602 (Aventis/Ajinomoto). It is still too early to speculate about the size of the market for VTAs, however, the current consensus is that the first drug could reach the market as early as 2007 and that this market has the potential of achieving $5 billion in annual sales 10 years after the launch of the first product. Vascular Targeting Agents, State of the Science & Strategic Opportunities, is a timely strategic consulting report from ASInsights designed to bring the latest happenings in both clinical development and marketing arena to the attention of oncology product managers in the pharmaceutical and medical biotech industries. The report examines the current state-of-the-science in the field. It assesses main products in development and their therapeutic mechanisms, profiles leading participants and gives estimates to their most likely time to market. It also provides market forecasts to the year 2010. Report Code: ASI0307-R110 Report Price: US$780.00 Standard User Report Price: US$2360.00 Corporate Site License for intranet Date Published: July 2003 Number of Pages: 75 Publisher: AS Insights Opportunity and Valuation Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_AS_Insights_Opportunity_and_Valuation_Reports__10.html#a141
|
|
| ||||||||